Bluejay Diagnostics (NASDAQ: BJDX) has reported its Q2 2025 business update, highlighting progress in its Symphony IL-6 test program. The company has initiated the SYMON-II pivotal clinical trial to validate findings from the successful SYMON-I pilot study, with completion expected by end of 2026 and FDA 510(k) submission targeted for 2027.
Key developments include a manufacturing partnership with SanyoSeiko Co. for the Symphony analyzer and an amended agreement with Toray Industries extending cartridge manufacturing timeline to October 2026. The company raised $3.85 million through warrant inducement financing in April 2025 but anticipates requiring additional capital through 2027 for manufacturing, clinical trials, and regulatory activities.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.